查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985507

心臟就地检验市场：全球市场预测（按产品类型、检测模式、技术、应用、最终用户和分销管道划分）- 2026-2032年

Cardiac Point of Care Testing Market by Product Type, Test Mode, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心臟即时检测市场价值将达到 105.6 亿美元，到 2026 年将成长至 118.8 亿美元，到 2032 年将达到 259.5 亿美元，复合年增长率为 13.70%。

主要市场统计数据
基准年 2025 105.6亿美元
预计年份：2026年 118.8亿美元
预测年份 2032 259.5亿美元
复合年增长率 (%) 13.70%

一个战略框架，用于理解为什么加速诊断反应和分散式心臟检测正在重塑临床路径和市场优先事项。

心臟就地检验正成为急性和慢性心血管疾病诊疗路径中的关键转捩点，它能够帮助医生在患者身边快速做出临床决策，并将诊断范围扩展到传统检查室之外。近期技术进步缩短了检测时间，并提高了分析灵敏度。同时，医疗保健的发展趋势推动了对在急诊诊所、门诊中心、居家医疗机构和医院检查室等场所进行分散式检查的需求不断增长。这些趋势正在改变临床医生对胸痛进行分诊、监测心臟衰竭以及评估心血管风险的方式，更快的诊断结果将带来更及时的干预措施和更有效率的诊疗路径。

生物标记灵敏度的提高、设备的微型化以及医疗保健服务体系的改革如何重新定义心臟诊断和临床工作流程。

床边心臟检测领域正经历一场变革，其驱动力来自于技术创新、临床实践的进步以及医疗服务体系的改革。高灵敏度生物标记检测延长了心肌损伤和心臟衰竭的诊断窗口期，因此需要重新评估分诊通讯协定，并缩短急诊和门诊的治疗时间。同时，生物感测器的微型化和诊断化学的进步使得在中心检查室之外也能获得可靠的定量结果，从而加速了向分散式、以患者为中心的诊断模式的广泛转变。

本检验了2025 年关税变化对营运和商业的影响，以及这些变化如何影响供应链的韧性、采购变化和定价策略。

2025年实施的累积关税措施为心臟就地检验生态系统带来了新的商业性和营运复杂性。进口零件、试剂原料和成品诊断设备关税带来的成本压力，促使製造商和经销商重新思考筹资策略和供应链结构。一些企业正在加快供应商多元化的步伐，例如优先选择关税较低地区的合作伙伴或寻求近岸外包方案，以降低贸易政策波动带来的风险。这些策略性因应措施不仅会对采购产生直接影响，还可能影响整个通路的产品定价和利润率。

透过对产品类型、最终用户需求、通路、测试模式、技术和临床应用进行详细的細項分析，揭示了有针对性的策略重点。

详细的細項分析揭示了临床需求、技术适用性和分销动态之间的交集，从而在整个心臟就地检验领域创造了差异化的机会。产品类型细分包括脑钠肽（BNP）、C反应蛋白、肌酸激酶MB（CK MB）、肌红蛋白和肌钙蛋白，其中BNP进一步细分为BNP和N端脑钠肽前体（Nt-proBNP），C反应蛋白细分为高灵敏度检测和标准检测，肌钙蛋白细分为肌钙蛋白I和肌钙蛋白T。终端使用者细分突显了门诊中心、急诊诊所、居家医疗服务和医院检查室的不同部署模式，每种模式都展现出独特的工作流程要求、人员能力和购买行为。分销管道包括医院药房、线上管道（包括B2B入口网站和D2C（直接面向消费者）服务）以及零售药房。每个管道都有不同的利润率预期和客户参与模式。

医疗保健基础设施、监管要求和製造生态系统方面的区域差异如何影响部署路径和策略市场进入方式？

区域趋势对心臟就地检验的推广路径、监管预期和供应链决策有显着影响。在美洲，临床应用主要受急诊对快速分诊的需求以及居家照护环境中对携带式诊断设备日益增长的需求所驱动，而公立和私立医疗系统的采购週期和报销机制则存在显着差异。欧洲、中东和非洲（EMEA）的情况则较为复杂，监管协调与市场分散并存，导致每种医疗器材和检测检测套组的推广路径各不相同。虽然集中式系统在某些地区仍然占据主导地位，但在其他地区，分散式检查正迅速普及，这主要得益于公共卫生优先事项和投资能力的推动。亚太地区兼具先进的都市区医疗设备系统（拥有完善的检测网路）和新兴经济体快速发展的基层医疗基础设施。此外，该地区的製造能力和供应商生态系统在全球供应链中扮演核心角色，影响采购决策和定价趋势。

竞争与伙伴关係的动态凸显了成熟和创新平台公司如何利用分销、连接和证据生成来确保可持续的市场地位。

就地检验的竞争动态由两类企业共同塑造：一类是成熟的诊断设备製造商，另一类是专注于特定领域的创新型企业，例如超灵敏生物标誌物、以用户为中心的设备设计以及整合式数位生态系统。大型平台公司通常利用其广泛的分销网络、完善的监管合规体係以及跨产品组合的协同效应来扩大产品部署，而新兴参与企业则专注于其平台的柔软性、低成本製造或能够实现快速迭代的新型生物感测器技术。

为製造商、经销商和医疗保健系统提供可操作且优先的行动方案，以加快部署速度、增强韧性，并使提供的服务与临床优先事项保持一致。

致力于加速技术普及并建立稳健业务营运的产业领导者应优先考虑一系列切实可行的策略，以平衡临床可靠性、供应链灵活性和终端用户体验。首先，投资于能够将就地检验与患者治疗路径中可衡量的改善联繫起来的临床证据，例如缩短决策时间、避免不必要的住院治疗，并确保这些证据能够涵盖各种终端用户场景，包括门诊中心、急诊诊所、居家医疗和医院检查室。其次，透过组装替代采购管道、尽可能将组装环节外包以及谈判包含价格保护条款的长期供应合同，实现供应链多元化并降低关税和贸易政策带来的风险。

透过调查方法，结合对临床医生的访谈、技术性能评估、监管审查和分销经济学，建构了一套严谨、多方面的分析。

本研究的综合分析是基于一种跨学科调查方法，旨在整合临床、技术、监管和商业性观点。主要资料来源包括对急诊医学和循环系统临床医生、门诊和住院采购负责人以及诊断设备製造商和分销合作伙伴的高管进行的结构化访谈，从而获得关于推广应用障碍和工作流程优先事项的定性见解。次要资讯来源包括对同行评审科学文献、监管指导文件以及近期发表的详细介绍设备审批、检测验证和互通性要求的出版物的系统性回顾。此外，还进行了技术评估，将生物感测器、免疫检测和横向流动化验等分析方法与临床性能标准和可用性指标进行比较。

简要概述相关人员应协调一致的临床、技术和操作要求，以最大限度地发挥分散式心臟诊断的潜力。

总之，心臟就地检验在现代心血管诊疗流程中发挥着至关重要的作用，并有望加快急诊、门诊和家庭环境中的临床决策。高灵敏度检测、生物感测器创新和数位化整合技术的进步正在拓展其应用场景，而不断变化的报销机制和法规环境也在影响其普及应用。然而，近期贸易政策的变化凸显了供应链韧性、成本透明度和适应性筹资策略对于维持竞争力以及确保诊断材料稳定供应的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：心臟就地检验市场：依产品类型划分

  • BNP
    • BNP
    • NT-proBNP
  • C反应蛋白
    • 高敏C反应蛋白
    • 标准C反应蛋白
  • CK MB
  • 肌红蛋白
  • 肌钙蛋白
    • 肌钙蛋白 I
    • 肌钙蛋白T

第九章 依检测模式就地检验市场

  • 定性
  • 定量

第十章：心臟就地检验市场：依技术划分

  • 生物感测器
    • 电化学感测器
    • 光学感测器
  • 免疫检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
  • 横向流动化验

第十一章 心臟就地检验市场：依应用领域划分

  • 心肌梗塞的诊断
  • 心臟衰竭监测
  • 风险评估

第十二章 心臟就地检验市场：依最终用户划分

  • 门诊部
  • 急诊诊所
  • 家庭医疗保健
  • 医院检查室

第十三章：心臟就地检验市场：依通路划分

  • 医院药房
  • 线上管道
    • B2B入口网站
    • 消费者
  • 零售药房

第十四章 心臟就地检验市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：心臟就地检验市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 心臟就地检验市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国心臟就地检验市场

第十八章：中国心臟就地检验市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardiac Insight Inc.
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio
  • Horiba, Ltd.
  • I-Sens Inc.
  • LifeSign LLC
  • Nexus Dx, Inc. by Sinocare
  • Nova Biomedical
  • PTS Diagnostics by Danaher Corporation
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trividia Health, Inc.
Product Code: MRR-3F5063247F53

The Cardiac Point of Care Testing Market was valued at USD 10.56 billion in 2025 and is projected to grow to USD 11.88 billion in 2026, with a CAGR of 13.70%, reaching USD 25.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.56 billion
Estimated Year [2026] USD 11.88 billion
Forecast Year [2032] USD 25.95 billion
CAGR (%) 13.70%

A strategic framing of why accelerated diagnostic responsiveness and decentralized cardiac testing are reshaping clinical pathways and market priorities

Cardiac point-of-care testing has emerged as a critical inflection point for acute and chronic cardiovascular care pathways, enabling faster clinical decision-making at the patient's side and expanding diagnostic reach beyond traditional laboratory settings. Recent technological advances have reduced assay run-times and improved analytical sensitivity, while healthcare delivery trends have driven demand for decentralized testing in emergency clinics, ambulatory care centers, home healthcare settings, and hospital laboratories. These dynamics are reshaping how clinicians triage chest pain, monitor heart failure, and stratify cardiovascular risk, with faster diagnostic results translating into more timely interventions and streamlined care pathways.

Concurrently, improvements in immunoassay platforms, lateral flow devices, and biosensor technologies are converging with digital integration and connectivity solutions, enabling more actionable data flows and remote monitoring capabilities. This shift is accompanied by evolving reimbursement and regulatory frameworks that are increasingly accommodating point-of-care modalities, albeit with variability across regions. Therefore, stakeholders-ranging from device manufacturers and distributors to hospital procurement teams and policy makers-must weigh clinical utility, workflow integration, and cost structures when evaluating adoption strategies.

This introduction frames the subsequent analysis by emphasizing clinical impact, technological progress, and operational considerations that together define strategic opportunities and risks in cardiac point-of-care testing.

How advances in biomarker sensitivity, device miniaturization, and care delivery reforms are jointly redefining cardiac diagnostics and clinical workflows

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by a combination of technological innovation, clinical practice evolution, and healthcare delivery reform. High-sensitivity biomarker assays have extended the diagnostic window for myocardial injury and heart failure, prompting emergency and ambulatory settings to re-evaluate triage protocols and reduce time-to-treatment. At the same time, biosensor miniaturization and improvements in assay chemistry have made reliable quantitative results feasible outside central laboratories, supporting a broader shift toward decentralized, patient-centric diagnostics.

These technology-driven advances are intersecting with shifting care models, where hospital-at-home initiatives, urgent care expansions, and remote monitoring programs are increasing demand for portable, rapid testing. Payment models that reward value-based outcomes and shorter hospital stays further incentivize adoption of point-of-care solutions that can demonstrably reduce length of stay and improve therapeutic targeting. In parallel, digital health integration and interoperability standards are creating expectations for secure data exchange and seamless inclusion of point-of-care results into electronic health records and clinical decision support systems.

Finally, competitive dynamics are changing as established diagnostics companies invest in connectivity and user-experience design, while agile medtech entrants focus on platform flexibility and cost-effective manufacturing. Collectively, these shifts are redefining where and how cardiac biomarkers are measured, how results influence care, and which capabilities will determine market leadership in the near term.

Examining the operational and commercial consequences of 2025 tariff changes and how they compel supply chain resilience, sourcing shifts, and pricing strategies

The introduction of cumulative tariff measures in 2025 has created a new layer of commercial and operational complexity for the cardiac point-of-care testing ecosystem. Tariff-driven cost pressures on imported components, reagent raw materials, and finished diagnostic devices have prompted manufacturers and distributors to reassess sourcing strategies and supply chain architectures. Some organizations have accelerated supplier diversification efforts, prioritizing partners in lower-tariff jurisdictions or pursuing nearshoring options to mitigate exposure to trade policy volatility. These strategic responses have immediate procurement implications and may influence product pricing and margin dynamics across distribution channels.

In practice, increased import costs have been met with a range of adaptations, including longer-term supplier contracts with price-protection clauses, localized assembly to avoid duties on finished goods, and redesigns that reduce dependence on tariff-affected materials. For end users, particularly smaller ambulatory centers and retail pharmacy channels, the pass-through of higher unit costs can constrain adoption momentum unless offset by demonstrable clinical and operational value. Payers and health systems are responding by scrutinizing total cost of care impacts, requiring clearer evidence that point-of-care testing shortens workflows or avoids downstream expenses.

Regulatory and customs processing delays associated with tariff implementation have also highlighted the need for robust inventory planning and buffer strategies. Overall, the tariff environment has elevated supply chain resilience and cost transparency as strategic priorities for manufacturers, distributors, and health system purchasers alike.

Detailed segmentation analysis connecting product categories, end-user requirements, distribution routes, test modes, technologies, and clinical applications to unlock targeted strategic priorities

A granular segmentation analysis reveals where clinical demand, technology fit, and distribution dynamics intersect to create differentiated opportunities across the cardiac point-of-care testing landscape. Product type segmentation encompasses BNP, C Reactive Protein, CK MB, Myoglobin, and Troponin, with further granularity for BNP split into BNP and Nt ProBNP, C Reactive Protein divided into High Sensitivity and Standard assays, and Troponin distinguished between Troponin I and Troponin T. End user segmentation highlights distinct adoption patterns across ambulatory care centers, emergency clinics, home healthcare services, and hospital laboratories, each presenting unique workflow requirements, staffing competencies, and purchasing behaviours. Distribution channels reflect hospital pharmacies, online channels-including Business To Business portals and Direct To Consumer offerings-and retail pharmacies, each channel imposing different margin expectations and customer engagement models.

Test mode segmentation bifurcates the market into qualitative and quantitative modalities, a distinction that maps closely to clinical intent and regulatory scrutiny, while technology segmentation identifies biosensor, immunoassay, and lateral flow assay approaches, with biosensors further categorized into electrochemical and optical sensors and immunoassays differentiated into chemiluminescence immunoassay and enzyme linked immunosorbent assay formats. Application-based segmentation captures the primary clinical use cases of diagnosis of myocardial infarction, heart failure monitoring, and risk assessment, which dictate performance thresholds and integration needs.

Understanding these interlocking segments allows stakeholders to prioritize product development and go-to-market strategies that align analytic performance with user setting, distribution economics, and clinical value propositions, ensuring that innovations address the most pressing unmet needs across care settings.

How regional differences in healthcare infrastructure, regulatory expectations, and manufacturing ecosystems shape adoption pathways and strategic market entry approaches

Regional dynamics exert a material influence on adoption pathways, regulatory expectations, and supply chain decisions within cardiac point-of-care testing. In the Americas, clinical adoption is driven by emergency department demand for rapid triage and by expanding home-based care initiatives that favour portable diagnostics, while procurement cycles and reimbursement mechanisms vary widely between public and private systems. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with market fragmentation, leading to differentiated pathways for devices and assays; in some areas, centralized systems remain dominant, whereas other markets show rapid uptake of decentralised testing, often influenced by public health priorities and investment capacity. Asia-Pacific displays a mix of advanced urban healthcare systems with sophisticated laboratory networks and rapidly expanding primary care infrastructures in emerging economies; this region's manufacturing capabilities and supplier ecosystems also play a central role in global supply chains, affecting sourcing decisions and price dynamics.

Each region imposes distinct requirements for clinical validation, quality systems, and distribution partnerships. For manufacturers and distributors, tailoring market entry strategies to these regional specifics-balancing regulatory timelines, channel selection, and local partnerships-will drive market traction. For healthcare providers and payers, regional context determines how point-of-care testing is prioritized within broader cardiovascular care initiatives and how value is assessed against competing clinical investments.

Competitive and partnership dynamics highlighting how platform incumbents and innovators leverage distribution, connectivity, and evidence generation to secure durable market positions

Competitive dynamics in cardiac point-of-care testing are shaped by a mix of established diagnostics manufacturers and agile innovators focusing on niche capabilities such as ultra-sensitive biomarkers, user-centric device design, and integrated digital ecosystems. Large-platform companies often leverage broad distribution networks, established regulatory footprints, and cross-portfolio synergies to scale introductions, while emerging entrants concentrate on platform flexibility, lower-cost manufacturing, or novel biosensor technologies that can be rapidly iterated.

Partnerships and strategic alliances are increasingly common as device developers seek to integrate assay expertise with connectivity providers and sample-to-result automation specialists. This collaborative approach accelerates time-to-market for features that matter to clinicians, such as real-time data transmission to electronic health records and decision-support compatibility. In addition, strategic licensing and OEM arrangements enable companies with strong commercial channels to offer complementary assays under co-branded or private-label models, expanding reach without duplicative infrastructure investments.

From a procurement perspective, health systems prioritize vendors that can demonstrate consistent supply, regulatory compliance, and clear pathways for technical support and training. Companies that invest in post-sales support models, local technical presence, and outcome-oriented evidence generation are best positioned to win durable contracts and to support broader clinical adoption across care settings.

Practical and prioritized actions for manufacturers, distributors, and health systems to accelerate adoption, enhance resilience, and align offerings with clinical priorities

Industry leaders seeking to accelerate adoption and build resilient operations should prioritize a set of actionable strategies that balance clinical credibility, supply chain agility, and end-user experience. First, invest in clinical evidence that links point-of-care testing to measurable improvements in patient pathways, such as reduced time-to-decision or avoidance of unnecessary admissions, and ensure that this evidence addresses different end-user contexts including ambulatory centers, emergency clinics, home healthcare, and hospital laboratories. Second, diversify supply chains to mitigate tariff and trade-policy exposure by developing alternate sourcing options, nearshoring assembly where feasible, and negotiating longer-term supply agreements with price protection.

Third, design product portfolios and distribution approaches tailored to channel economics; hospital pharmacies, online channels including B2B portals and direct-to-consumer routes, and retail pharmacies each require distinct pricing, packaging, and service propositions. Fourth, prioritize interoperability and digital integration so that point-of-care results feed seamlessly into clinical workflows and electronic records, thereby increasing clinical utility and adoption. Fifth, adopt a segmented go-to-market strategy that aligns technologies-whether biosensors, immunoassays, or lateral flow formats-with the specific performance requirements of applications such as myocardial infarction diagnosis, heart failure monitoring, and risk assessment.

By combining robust clinical evidence, supply chain resilience, channel-specific commercial design, digital enablement, and targeted segmentation, industry leaders can create defensible positions and accelerate sustainable uptake of cardiac point-of-care testing solutions.

Methodological approach integrating clinician interviews, technical performance assessments, regulatory reviews, and channel economics to build a rigorous multi-perspective analysis

This research synthesis draws on a multidisciplinary methodology designed to integrate clinical, technological, regulatory, and commercial perspectives. Primary inputs included structured interviews with clinicians in emergency medicine and cardiology, procurement professionals across ambulatory and hospital settings, and executives from diagnostic companies and distribution partners, providing qualitative insight into adoption barriers and workflow priorities. Secondary inputs comprised a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and recent public filings that detail device clearances, assay validations, and interoperability requirements. Additionally, technology assessments were conducted to compare analytical approaches such as biosensors, immunoassays, and lateral flow assays against clinical performance criteria and usability metrics.

Analytical frameworks incorporated segmentation mapping to relate product types and technologies to end-user needs and distribution economics, along with scenario analysis to evaluate operational responses to external pressures such as tariff changes. Care was taken to ensure source triangulation, cross-validating claims from interviews with published validation studies and regulatory documentation. Limitations of the methodology include variable transparency in proprietary supplier cost structures and the evolving nature of trade policy and reimbursement pathways, which may influence implementation timelines. Nonetheless, the approach provides a rigorous basis for strategic decision-making by combining clinician perspectives, technical performance evaluation, and commercial channel analysis.

A concise synthesis of clinical, technological, and operational imperatives that stakeholders must align to realize the full potential of decentralized cardiac diagnostics

In conclusion, cardiac point-of-care testing occupies a pivotal role in modern cardiovascular care pathways, offering the potential to accelerate clinical decision-making across emergency, ambulatory, and home-based settings. The convergence of high-sensitivity assays, biosensor innovations, and improved digital integration is expanding the range of viable use cases, while evolving reimbursement and regulatory contexts are shaping adoption trajectories. However, recent trade-policy shifts underline the importance of supply chain resilience, cost transparency, and adaptive sourcing strategies to maintain competitive positioning and ensure consistent access to diagnostic supplies.

For stakeholders, the imperative is clear: align product performance with specific clinical workflows, demonstrate measurable impacts on patient management, and design distribution and support models that reflect the economic realities of each end-user segment. Companies that combine robust clinical evidence, flexible manufacturing and sourcing approaches, and strong post-sales support will be best positioned to convert technical promise into sustained clinical and commercial success. Moving forward, continued collaboration among manufacturers, clinicians, payers, and regulators will be essential to realize the full potential of decentralized cardiac diagnostics while maintaining quality, affordability, and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Point of Care Testing Market, by Product Type

  • 8.1. BNP
    • 8.1.1. BNP
    • 8.1.2. Nt ProBNP
  • 8.2. C Reactive Protein
    • 8.2.1. High Sensitivity C Reactive Protein
    • 8.2.2. Standard C Reactive Protein
  • 8.3. CK MB
  • 8.4. Myoglobin
  • 8.5. Troponin
    • 8.5.1. Troponin I
    • 8.5.2. Troponin T

9. Cardiac Point of Care Testing Market, by Test Mode

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cardiac Point of Care Testing Market, by Technology

  • 10.1. Biosensor
    • 10.1.1. Electrochemical Sensor
    • 10.1.2. Optical Sensor
  • 10.2. Immunoassay
    • 10.2.1. Chemiluminescence Immunoassay
    • 10.2.2. Enzyme Linked Immunosorbent Assay
  • 10.3. Lateral Flow Assay

11. Cardiac Point of Care Testing Market, by Application

  • 11.1. Diagnosis Of Myocardial Infarction
  • 11.2. Heart Failure Monitoring
  • 11.3. Risk Assessment

12. Cardiac Point of Care Testing Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Emergency Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospital Laboratories

13. Cardiac Point of Care Testing Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Channels
    • 13.2.1. Business To Business Portals
    • 13.2.2. Direct To Consumer
  • 13.3. Retail Pharmacies

14. Cardiac Point of Care Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cardiac Point of Care Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cardiac Point of Care Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cardiac Point of Care Testing Market

18. China Cardiac Point of Care Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abaxis, Inc. by Zoetis Inc
  • 19.6. Abbott Laboratories
  • 19.7. ACON Laboratories, Inc.
  • 19.8. Beckman Coulter
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories, Inc.
  • 19.11. bioMerieux SA
  • 19.12. Cardiac Insight Inc.
  • 19.13. CardioGenics Holdings Inc.
  • 19.14. Chembio Diagnostic Systems, Inc. by Biosynex
  • 19.15. EKF Diagnostics
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Fujirebio
  • 19.18. Horiba, Ltd.
  • 19.19. I-Sens Inc.
  • 19.20. LifeSign LLC
  • 19.21. Nexus Dx, Inc. by Sinocare
  • 19.22. Nova Biomedical
  • 19.23. PTS Diagnostics by Danaher Corporation
  • 19.24. Quidel Corporation
  • 19.25. Radiometer Medical ApS
  • 19.26. Randox Laboratories Ltd.
  • 19.27. Siemens Healthineers AG
  • 19.28. Thermo Fisher Scientific Inc.
  • 19.29. Trividia Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 285. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CARDIAC POINT OF CARE TESTING MARKE